XERS vs. JANX, TARS, IDYA, AGIO, SDGR, NAMS, APGE, BLTE, TVTX, and IRON
Should you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include Janux Therapeutics (JANX), Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), Schrödinger (SDGR), NewAmsterdam Pharma (NAMS), Apogee Therapeutics (APGE), Belite Bio (BLTE), Travere Therapeutics (TVTX), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry.
Xeris Biopharma vs.
Xeris Biopharma (NASDAQ:XERS) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking.
Xeris Biopharma has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 3.16, indicating that its share price is 216% more volatile than the S&P 500.
Xeris Biopharma received 102 more outperform votes than Janux Therapeutics when rated by MarketBeat users. However, 71.19% of users gave Janux Therapeutics an outperform vote while only 69.90% of users gave Xeris Biopharma an outperform vote.
In the previous week, Janux Therapeutics had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 2 mentions for Janux Therapeutics and 1 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.54 beat Janux Therapeutics' score of 1.16 indicating that Xeris Biopharma is being referred to more favorably in the media.
Xeris Biopharma currently has a consensus target price of $5.15, indicating a potential upside of 43.45%. Janux Therapeutics has a consensus target price of $89.90, indicating a potential upside of 147.18%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Janux Therapeutics is more favorable than Xeris Biopharma.
42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 4.6% of Xeris Biopharma shares are held by insiders. Comparatively, 29.4% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Xeris Biopharma has a net margin of -33.69% compared to Janux Therapeutics' net margin of -463.91%. Xeris Biopharma's return on equity of 0.00% beat Janux Therapeutics' return on equity.
Janux Therapeutics has lower revenue, but higher earnings than Xeris Biopharma. Janux Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Janux Therapeutics beats Xeris Biopharma on 12 of the 19 factors compared between the two stocks.
Get Xeris Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Xeris Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:XERS) was last updated on 2/17/2025 by MarketBeat.com Staff